DK3036329T3 - Immunonkolytiske terapier - Google Patents
Immunonkolytiske terapier Download PDFInfo
- Publication number
- DK3036329T3 DK3036329T3 DK14837931.6T DK14837931T DK3036329T3 DK 3036329 T3 DK3036329 T3 DK 3036329T3 DK 14837931 T DK14837931 T DK 14837931T DK 3036329 T3 DK3036329 T3 DK 3036329T3
- Authority
- DK
- Denmark
- Prior art keywords
- immunoncolytical
- therapies
- immunoncolytical therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868978P | 2013-08-22 | 2013-08-22 | |
| PCT/US2014/052308 WO2015027163A1 (en) | 2013-08-22 | 2014-08-22 | Immuno-oncolytic therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3036329T3 true DK3036329T3 (da) | 2021-01-11 |
Family
ID=52484194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14837931.6T DK3036329T3 (da) | 2013-08-22 | 2014-08-22 | Immunonkolytiske terapier |
| DK20189155.3T DK3778897T3 (da) | 2013-08-22 | 2014-08-22 | Immunonkolytiske terapier |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20189155.3T DK3778897T3 (da) | 2013-08-22 | 2014-08-22 | Immunonkolytiske terapier |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11478518B2 (da) |
| EP (3) | EP3778897B1 (da) |
| JP (3) | JP6912199B2 (da) |
| KR (1) | KR102389240B1 (da) |
| CN (1) | CN105658795B (da) |
| AU (1) | AU2014308648B2 (da) |
| CA (3) | CA3213715A1 (da) |
| DK (2) | DK3036329T3 (da) |
| EA (1) | EA037582B1 (da) |
| ES (1) | ES2847305T3 (da) |
| FI (1) | FI3778897T3 (da) |
| HK (1) | HK1223402A1 (da) |
| HR (1) | HRP20240078T1 (da) |
| IL (1) | IL243996A0 (da) |
| LT (1) | LT3778897T (da) |
| MD (2) | MD4748C1 (da) |
| MX (1) | MX2016002257A (da) |
| NZ (1) | NZ716825A (da) |
| PE (1) | PE20160673A1 (da) |
| PH (1) | PH12016500329A1 (da) |
| PL (1) | PL3778897T3 (da) |
| PT (1) | PT3778897T (da) |
| RS (1) | RS65104B1 (da) |
| SG (1) | SG11201600960PA (da) |
| SI (1) | SI3778897T1 (da) |
| WO (1) | WO2015027163A1 (da) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102389240B1 (ko) * | 2013-08-22 | 2022-04-20 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 면역-종양 살상 요법 |
| JP2018510143A (ja) | 2015-02-25 | 2018-04-12 | メモリアル スローン ケタリング キャンサー センター | 不活化非複製改変ワクシニアウイルスアンカラ（ｍｖａ）の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用 |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| JP6452266B2 (ja) * | 2015-07-22 | 2019-01-16 | 国立大学法人鳥取大学 | ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子 |
| CN108350434B (zh) * | 2015-09-08 | 2022-06-07 | 新罗杰股份有限公司 | 表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法 |
| AU2016349632A1 (en) | 2015-11-07 | 2018-05-24 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| JP7025339B2 (ja) | 2016-02-25 | 2022-02-24 | メモリアル スローン ケタリング キャンサー センター | 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス |
| WO2017147554A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| EP3432863A4 (en) * | 2016-03-25 | 2019-11-13 | University of Pittsburgh - of The Commonwealth System of Higher Education | SYNTHETICALLY COVED VIRUS |
| EP3254692A1 (en) | 2016-06-10 | 2017-12-13 | Ceva Sante Animale | Multivalent recombinant spv |
| EP3488005A4 (en) | 2016-07-19 | 2020-07-29 | University of Pittsburgh- Of the Commonwealth System of Higher Education | TARGETING ONCOLYTIC VIRUSES STAT3 |
| KR20190059297A (ko) * | 2016-09-21 | 2019-05-30 | 스티븐 에이치. 쏜 | 고-이동성 군 박스 1 돌연변이체 |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| AU2017375958A1 (en) | 2016-12-12 | 2019-07-04 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| JP2020514324A (ja) * | 2017-02-03 | 2020-05-21 | ユニバーシティ オブ ピッツバーグ −オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 腫瘍溶解性ウイルス療法 |
| CN111373259A (zh) * | 2017-03-06 | 2020-07-03 | 塔拉里斯治疗股份有限公司 | 测定治疗性细胞组合物的效力的方法和组合物 |
| WO2018195552A1 (en) * | 2017-04-21 | 2018-10-25 | Sillajen, Inc. | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| EP3973973A1 (en) * | 2017-10-31 | 2022-03-30 | KaliVir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
| EP3717000A1 (en) | 2017-12-01 | 2020-10-07 | Gerd Sutter | Immuno-modulated replication-efficient vaccinia virus strain |
| SG11202006457YA (en) | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
| EP3768698A4 (en) | 2018-03-19 | 2022-03-30 | MultiVir Inc. | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSIVE GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER |
| WO2020018996A2 (en) * | 2018-07-20 | 2020-01-23 | Ansun Biopharma, Inc. | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
| KR20210132003A (ko) * | 2018-12-21 | 2021-11-03 | 오타와 하스피털 리서치 인스티튜트 | 변형된 오르토폭스 바이러스 벡터 |
| CA3125020A1 (en) * | 2019-01-07 | 2020-07-16 | Kalivir Immunotherapeutics, Inc. | Methods of treating cancer |
| WO2020148612A1 (en) * | 2019-01-14 | 2020-07-23 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| US11685904B2 (en) | 2019-02-14 | 2023-06-27 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| EP4045657A4 (en) * | 2019-10-16 | 2023-11-15 | KaliVir Immunotherapeutics, Inc. | MODIFIED EXTRACELLULAR ENVELOPED VIRUS |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| IL293627A (en) * | 2019-12-12 | 2022-08-01 | Ignite Immunotherapy Inc | Variant of oncolytic vaccinia virus and methods of using it |
| CA3167002A1 (en) * | 2020-01-09 | 2021-07-15 | Pfizer Inc. | Recombinant vaccinia virus |
| JP2024516400A (ja) * | 2021-04-30 | 2024-04-15 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 修飾されたｍｈｃ発現のための腫瘍溶解性ウイルス |
| AU2022303363A1 (en) * | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1578396A4 (en) * | 2002-08-12 | 2007-01-17 | David Kirn | METHODS AND COMPOSITIONS RELATING TO POXVIRUS AND CANCER |
| WO2007023725A1 (ja) * | 2005-08-25 | 2007-03-01 | Yokohama City University | 遺伝子ワクチン |
| WO2007030668A2 (en) | 2005-09-07 | 2007-03-15 | Jennerex Biotherapeutics Ulc | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| US8980246B2 (en) * | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| AU2012244210B2 (en) * | 2005-09-07 | 2014-10-02 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| KR20080084528A (ko) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| WO2009124044A2 (en) * | 2008-03-31 | 2009-10-08 | University Of Florida Research Foundation, Inc. | Tumor growth inhibition via conditioning of tumor microenvironment |
| CN103347393A (zh) | 2009-09-14 | 2013-10-09 | 杰能斯有限公司 | 溶瘤牛痘病毒组合癌症疗法 |
| US20130202639A1 (en) | 2010-03-25 | 2013-08-08 | Konstantin G. Kousoulas | Synthetic Herpes Simplex Viruses for Treatment of Cancers |
| EA201301173A1 (ru) * | 2011-04-15 | 2015-08-31 | Дженелюкс Корпорейшн | Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| KR102389240B1 (ko) | 2013-08-22 | 2022-04-20 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 면역-종양 살상 요법 |
-
2014
- 2014-08-22 KR KR1020167006785A patent/KR102389240B1/ko active IP Right Grant
- 2014-08-22 EA EA201690444A patent/EA037582B1/ru unknown
- 2014-08-22 PE PE2016000287A patent/PE20160673A1/es unknown
- 2014-08-22 LT LTEP20189155.3T patent/LT3778897T/lt unknown
- 2014-08-22 MD MDA20180086A patent/MD4748C1/ro active IP Right Grant
- 2014-08-22 CA CA3213715A patent/CA3213715A1/en active Pending
- 2014-08-22 EP EP20189155.3A patent/EP3778897B1/en active Active
- 2014-08-22 CA CA2921041A patent/CA2921041C/en active Active
- 2014-08-22 AU AU2014308648A patent/AU2014308648B2/en active Active
- 2014-08-22 EP EP14837931.6A patent/EP3036329B1/en active Active
- 2014-08-22 CN CN201480058401.0A patent/CN105658795B/zh active Active
- 2014-08-22 SI SI201432060T patent/SI3778897T1/sl unknown
- 2014-08-22 DK DK14837931.6T patent/DK3036329T3/da active
- 2014-08-22 NZ NZ716825A patent/NZ716825A/en unknown
- 2014-08-22 DK DK20189155.3T patent/DK3778897T3/da active
- 2014-08-22 CA CA3213683A patent/CA3213683A1/en active Pending
- 2014-08-22 FI FIEP20189155.3T patent/FI3778897T3/fi active
- 2014-08-22 SG SG11201600960PA patent/SG11201600960PA/en unknown
- 2014-08-22 ES ES14837931T patent/ES2847305T3/es active Active
- 2014-08-22 HR HRP20240078TT patent/HRP20240078T1/hr unknown
- 2014-08-22 PT PT201891553T patent/PT3778897T/pt unknown
- 2014-08-22 PL PL20189155.3T patent/PL3778897T3/pl unknown
- 2014-08-22 EP EP23215391.6A patent/EP4324918A3/en active Pending
- 2014-08-22 WO PCT/US2014/052308 patent/WO2015027163A1/en active Application Filing
- 2014-08-22 RS RS20240082A patent/RS65104B1/sr unknown
- 2014-08-22 MX MX2016002257A patent/MX2016002257A/es unknown
- 2014-08-22 MD MD20160027A patent/MD4624C1/ro active IP Right Grant
- 2014-08-22 JP JP2016536482A patent/JP6912199B2/ja active Active
-
2016
- 2016-02-07 IL IL243996A patent/IL243996A0/en unknown
- 2016-02-18 PH PH12016500329A patent/PH12016500329A1/en unknown
- 2016-02-19 US US15/048,698 patent/US11478518B2/en active Active
- 2016-10-12 HK HK16111742.0A patent/HK1223402A1/zh unknown
-
2019
- 2019-07-19 JP JP2019133264A patent/JP7021154B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015459A patent/JP7333431B2/ja active Active
- 2022-09-07 US US17/939,707 patent/US20230008089A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3778897T3 (da) | Immunonkolytiske terapier | |
| DK3342773T3 (da) | Syk-hæmmere | |
| DK3613453T3 (da) | Fordamper | |
| DK3077047T3 (da) | Aramcholsalte | |
| DK3060460T3 (da) | Saddel | |
| DK3027598T3 (da) | Oxoquinazolinyl-butanamidderivater | |
| DK2956698T5 (da) | Bindestrimler | |
| DK3052081T3 (da) | Pastil | |
| DK2946640T3 (da) | Langmuir-probe | |
| DK3071227T3 (da) | Fiskevaccine | |
| DE102013106534B8 (de) | Chromatographiepipettenspitze | |
| DE112014001252A5 (de) | Aufbissschiene | |
| DK2981168T3 (da) | Laminitiskile | |
| DK3086679T3 (da) | Sportssko | |
| FI10343U1 (fi) | Mittateippi | |
| FI10138U1 (fi) | Kelkkateltta | |
| ES1078715Y (es) | Mosquitera | |
| DE112014005422A5 (de) | Friktionsfalschdrallaggregat | |
| BR112016000501A2 (pt) | Nalador | |
| FI10396U1 (fi) | Tielana | |
| FI10399U1 (fi) | Klapivaste | |
| ES1100380Y (es) | Trompo | |
| ES1093505Y (es) | Aerociclo | |
| ES1096481Y (es) | Ecofregona | |
| ES1093455Y (es) | Columbario |